Healthcare can be complicated.
Your cardiology news shouldn’t be.

Join thousands of cardiology leaders today.

Value-Based Care October 9, 2023

CVAUSA and InnovaCare’s Value-Based Alliance October 9, 2023

A new Cardiovascular Associates of America and InnovaCare Health is aiming to create a new model for cardiology + primary care VBC delivery.

Cardiology October 5, 2023

MedAxiom on the State of Cardiovascular Providers October 5, 2023

MedAxiom just released its 11th annual Compensation and Production Report, revealing general stability in 2022 after years of significant change.

Surgeries & Interventions October 2, 2023

Adena Health Pauses Cardiac Surgeries Amid Mounting Controversies October 2, 2023

Ohio’s Adena Health System has temporarily stopped performing heart surgeries, after months of growing scrutiny and some troubling deaths.

Population Health September 28, 2023

The CDC’s Heavy Obesity Update September 28, 2023

Obesity is easily among the leading cardiovascular disease risk factors, and its overall impact on public cardiovascular health could be rising faster than many of us might imagine. In just 10 years, the U.S. went from having zero states with an obesity prevalence above 35% to a whopping 22 states in 2022.

Cardiology September 25, 2023

Cardiovascular Societies Seek A Board of Their Own September 25, 2023

After months of growing cardiologist backlash against the ABIM’s Maintenance of Certification program, four leading cardiovascular societies collectively announced plans to create a new cardiology board to replace it.

Pharmaceuticals September 21, 2023

Abelacimab Significantly Reduces Bleeding September 21, 2023

Anthos Therapeutics celebrated its Phase II results showing that its Factor XI inhibitor abelacimab significantly reduced bleeding among AFib patients compared to rivaroxaban.

Cardiology September 18, 2023

Cardiology in 2073 September 18, 2023

Most of cardiology today was unknown or in its very early stages fifty years ago, and this forecast suggests that “cardiology will change as much in the next 50 years.”

Pharmaceuticals September 14, 2023

Lorundrostat’s Safe and Effective Blood Pressure Control September 14, 2023

An aldosterone inhibitor called lorundrostat took a step towards becoming the first new antihypertensive agent class in nearly 15 years, after safely and effectively treating patients with uncontrolled blood pressure in a Phase II trial.

Pharmaceuticals September 11, 2023

Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact September 11, 2023

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

Artificial Intelligence September 7, 2023

The State of Cardiology AI September 7, 2023

The cardiology AI segment is showing more clinical and commercial promise than just about any AI segment in healthcare outside of radiology, and its rapid evolution is worth our attention. Because of that, we’re taking a deep dive into the state of cardiology AI and the key trends driving its growth.

Electrophysiology August 31, 2023

Most Subclinical AF Patients Better Off Without Anticoagulants August 31, 2023

The growing number of people walking around with implantable and wearable cardiac monitoring devices will undoubtedly lead to far more subclinical AFib detections. But the NOAH-AFNET 6 trial provided some much needed reassurance that many of these patients would be better off without anticoagulants.

Surgeries & Interventions August 28, 2023

ReCor Medical Takes Renal Denervation Lead Following FDA Panel Review August 28, 2023

The renal denervation votes are in, and they’re pointing in very different directions for ReCor Medical and Medtronic’s respective RDN devices. The companies argued their premarket approval cases to an FDA expert panel last week, and only ReCor walked away with panel support.

Cardiology Testing August 24, 2023

Simplifying CVD and Renal Assessments with Multimarker Blood Testing August 24, 2023

Blood biomarker tests play a key role in assessing cardiovascular and renal risks in diabetic patients, but a recent AHA study out of Harvard Medical School suggests that a “simple” new multimarker test could significantly improve these assessments and downstream treatment decisions.

Cardiology Guidelines August 21, 2023

HFrEF Treatment’s Guideline Barrier August 21, 2023

Guideline-directed medical therapies (GDMT) for heart failure have proven to be “profoundly effective at reducing morbidity and mortality,” and yet prescription rates for many HFrEF therapies are far too low and inconsistent. To unravel this challenge, a UCLA team analyzed VA data from 178k veterans in 306 Hospital Referral Regions (HRRs) across the US.

Electrophysiology August 17, 2023

Questioning the Cath Lab for Arrhythmia Risk Management August 17, 2023

Many arrhythmia patients take a trip to the cath lab before they end up in the EP lab, but a pair of new studies suggest that many of these “risk management” cath lab procedures are unnecessary - and might even increase risks.

Pharmaceuticals August 14, 2023

Novo Nordisk Expands Weight Loss Pipeline with Inversago Acquisition August 14, 2023

Novo Nordisk added to its leadership position in the white hot weight loss segment, acquiring Canadian biotech Inversago Pharma for up to $1.075 billion depending on certain development and commercial milestones.

Pharmaceuticals August 10, 2023

Wegovy Cuts Weight and Cardiovascular Events August 10, 2023

The hottest medication in the world got even hotter this week after Novo Nordisk revealed that its weight loss drug Wegovy (semaglutide) also reduces major cardiac event risks by 20% - a revelation that could change how GLP-1s are used, perceived, and reimbursed.

Pharmaceuticals August 7, 2023

Novartis and Ionis Double Down on Lp(a) August 7, 2023

Novartis and Ionis Pharmaceuticals doubled down on their Lp(a) alliance, launching a second collaboration focused on developing and commercializing a treatment for patients with lipoprotein(a)-driven cardiovascular disease.

Digital Health August 3, 2023

Hims’ Dual-Action Cardiovascular Health Expansion August 3, 2023

Massive direct-to-consumer health and wellness company, Hims & Hers, announced an unexpected expansion into cardiovascular care last week with the launch of Heart Health by Hims.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!